IceCure Medical Ltd. Ordinary Shares (ICCM) is a publicly traded Healthcare sector company. As of May 19, 2026, ICCM trades at $0.22 with a market cap of $18.67M and a P/E ratio of 0.00. ICCM moved -0.32% today. Year to date, ICCM is -65.08%; over the trailing twelve months it is -78.85%. Its 52-week range spans $0.22 to $1.66. Analyst consensus is buy with an average price target of $1.00. Rallies surfaces ICCM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IceCure ProSense® Achieves 89.4% Renal RFR and 100% Breast Cryoablation Success: At ECIO 2026, IceCure presented ICESECRET 5-year data showing 89.4% recurrence-free rate for renal tumors ≤3 cm and 83.9% recurrence-free at median four-year follow-up following ProSense® cryoablation. Independent studies reported 100% no residual disease in 28 early-stage breast tumors at 12 months and 92.9% fibroadenoma volume reduction at one year.
| Metric | Value |
|---|---|
| Price | $0.22 |
| Market Cap | $18.67M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.66 |
| 52-Week Low | $0.22 |
| Volume | 1.10M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
2 analysts cover ICCM: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $1.00.